Hutchison China Meditech Limited Grant of Share Options under Share Option Scheme (2681I)

TIDMHCM

RNS Number : 2681I

Hutchison China Meditech Limited

20 March 2018

Grant of Share Options under Share Option Scheme

London: Tuesday, March 20, 2018: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on March 19, 2018, it granted share options under the Share Option Scheme adopted by Chi-Med at its Annual General Meeting on April 24, 2015 (the "Share Option Scheme").

Chi-Med granted 150,000 share options under its Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees. Details of such share options granted prescribed are as follows:

 
 Date of grant             :   March 19, 2018 
 Exercise price of share   :   GBP49.74 per Ordinary Share 
  options granted 
 Number of share options   :   150,000 (each share option 
  granted                       shall entitle the holder 
                                thereof to subscribe for 
                                one Ordinary Share) 
 Closing market price      :   GBP48.45 per Ordinary Share 
  of Ordinary Shares on 
  the date of grant 
 Validity period of the    :   From March 19, 2018 to March 
  share options                 18, 2028 
 

100,000 of the 150,000 share options were granted to Dr Weiguo Su, Executive Director and Chief Scientific Officer, being a person discharging managerial responsibility under the EU Market Abuse Regulation.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 
 1       Details of the person discharging managerial responsibilities/person closely associated 
 
   a)      Name                                                     Dr Weiguo Su 
        -------------------------------------------------------  ----------------------------------------------------- 
 2       Reason for the notification 
        -------------------------------------------------------------------------------------------------------------- 
 
   a)      Position/status                                          Executive Director and Chief Scientific Officer 
        -------------------------------------------------------  ----------------------------------------------------- 
 
   b)      Initial notification/Amendment                           Initial notification 
        -------------------------------------------------------  ----------------------------------------------------- 
 3       Details of the issuer, emission allowance market participant, auction platform, auctioneer 
          or auction monitor 
        -------------------------------------------------------------------------------------------------------------- 
 
   a)      Name                                                     Hutchison China MediTech Limited 
        -------------------------------------------------------  ----------------------------------------------------- 
 
   b)      LEI                                                      2138006X34YDQ6OBYE79 
        -------------------------------------------------------  ----------------------------------------------------- 
 4       Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
          each type of transaction; (iii) each date; and (iv) each place where transactions have been 
          conducted 
        -------------------------------------------------------------------------------------------------------------- 
 
   a)     Description of the financial instrument, type of         Option over Ordinary Share of US$1.00 
          instrument 
 
          Identification code 
                                                                   Option over Ordinary Share with DI ISIN: 
                                                                   KYG4672N1016 
        -------------------------------------------------------  ----------------------------------------------------- 
 
   b)      Nature of the transaction                               Grant of options in respect of 100,000 Ordinary 
                                                                   Shares under the Share Option Scheme. 
 
                                                                   The share options granted are exercisable subject 
                                                                   to a vesting schedule of 25% on each of 
                                                                   the first, second, third and fourth anniversaries 
                                                                   of the effective date of grant. 
        -------------------------------------------------------  ----------------------------------------------------- 
                                                                       Price(s)           Volume(s) 
   c)      Price(s) and volume(s)                                               Nil               100,000 
                                                                                      ------------------- 
        -------------------------------------------------------  ----------------------------------------------------- 
 
   d)      Aggregated information                                   N/A 
           -  Aggregated volume 
           -  Price 
        -------------------------------------------------------  ----------------------------------------------------- 
 
   e)      Date of the transaction                                  2018-03-19 
        -------------------------------------------------------  ----------------------------------------------------- 
 
   f)      Place of the transaction                                 Outside a trading venue 
        -------------------------------------------------------  ----------------------------------------------------- 
 

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (SEHK: 1). For more information, please visit: www.chi-med.com.

Forward Looking Statements

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM. Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President, Corporate Finance 
 & Development                                       [phone] 
 
U.K. & International Media Enquiries 
Anthony Carlisle, Citigate Dewe Rogerson             [phone] (Mobile)   [e-mail] 
 
U.S. Based Media Enquiries 
Brad Miles, BMC Communications                       [phone] (Mobile)  [e-mail] 
Susan Duffy, BMC Communications                      [phone] (Mobile)  [e-mail] 
 
Investor Relations 
Matt Beck, The Trout Group                           [phone] (Mobile)  [e-mail] 
David Dible, Citigate Dewe Rogerson                  [phone] (Mobile)   [e-mail] 
 
Panmure Gordon (UK) Limited 
Richard Gray / Andrew Potts                          [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHPGUQAWUPRURU

(END) Dow Jones Newswires

March 20, 2018 05:15 ET (09:15 GMT)